Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Scientists Investigate the Relationship Between the ABCB1 Gene and Lyme Disease

Ticks transmit Borrelia burgdorferi bacteria to humans, causing Lyme disease. Doctors treat this condition with antibiotic medications, but some patients still experience chronic Lyme disease or post-treatment Lyme disease syndrome (PTLDS). Chronic Lyme disease symptoms include fatigue, pain, and cognitive difficulties that significantly impact quality of life.

The ABCB1 gene, also known as MDR1, plays a crucial role in medication effectiveness and the development of chronic Lyme disease. The protein P-glycoprotein (P-gp), encoded by the ABCB1 gene, helps eliminate toxic bacterial products and pathogenic substances from cells. However, this protective mechanism can also reduce the effectiveness of medications.

Individuals with specific genetic variants in the ABCB1 gene may require higher medication dosages for various conditions, including antidepressants, HIV treatments, and chemotherapy. Certain genetic factors can lead to treatment failure in some individuals.

Research suggests that individuals with multiple P-gp-reducing variants in the ABCB1 gene are at a higher risk of developing chronic Lyme disease after a Borrelia infection. Specific genetic variants, such as rs1128503, rs2235067, and rs4148740, have been linked to an increased risk of chronic Lyme disease.

Genetic testing for ABCB1 gene variants can provide valuable insights into an individual's risk for chronic Lyme disease. By working with healthcare providers to interpret genetic test results, individuals can develop personalized treatment plans and preventive strategies based on their genetic profile.

Lifestyle modifications, such as adopting a healthier diet, managing stress, and implementing tick bite prevention strategies, can help reduce the risk of Lyme disease and its long-term effects.

Understanding the connection between chronic Lyme disease and the ABCB1 gene underscores the importance of genetic factors in infection risk and treatment outcomes. By leveraging personalized health reports and genetic insights, individuals can take proactive steps to manage their health in partnership with healthcare professionals.

Practical Advice:

  1. Genetic Testing: Consider getting assessed for ABCB1 gene variants through PlexusDx's Precision Health & Wellness tests to understand your risk for chronic Lyme disease.
  2. Consultation: Collaborate with your healthcare provider to interpret genetic test results and develop tailored treatment plans based on your genetic makeup.
  3. Lifestyle Modifications: Make lifestyle changes, such as improving your diet, managing stress, and practicing tick bite prevention, to lower your risk of Lyme disease and its lingering effects.

For more information on Precision Health & Wellness tests by PlexusDx, visit PlexusDx.com or find them on Amazon and Walmart.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.